State Street Corp Decreases Position in AnaptysBio, Inc. (NASDAQ:ANAB)

State Street Corp lessened its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 6.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 906,182 shares of the biotechnology company’s stock after selling 60,670 shares during the quarter. State Street Corp’s holdings in AnaptysBio were worth $30,357,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. FMR LLC increased its stake in AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after purchasing an additional 438,557 shares during the period. Frazier Life Sciences Management L.P. increased its stake in AnaptysBio by 140.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after buying an additional 1,265,891 shares during the period. Assenagon Asset Management S.A. lifted its holdings in AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after buying an additional 168,813 shares in the last quarter. Jennison Associates LLC bought a new stake in AnaptysBio during the 3rd quarter valued at about $8,874,000. Finally, Victory Capital Management Inc. boosted its position in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after buying an additional 206,750 shares during the period.

AnaptysBio Stock Down 3.0 %

Shares of AnaptysBio stock opened at $14.55 on Friday. AnaptysBio, Inc. has a 52-week low of $14.19 and a 52-week high of $41.31. The firm’s 50 day moving average price is $23.87 and its 200-day moving average price is $29.18. The company has a market cap of $442.74 million, a P/E ratio of -2.39 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, equities research analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. The trade was a 8.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ANAB has been the subject of several research analyst reports. Wells Fargo & Company decreased their price target on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. UBS Group lifted their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wedbush reissued an “outperform” rating and set a $40.00 price target (down previously from $42.00) on shares of AnaptysBio in a research report on Wednesday, December 11th. JPMorgan Chase & Co. decreased their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday. Finally, HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $52.00 to $19.00 in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.